The SGLT2 inhibitors, initially developed as hypoglycemic agents, have demonstrated an important cardiorenal protective effect in patients with and without diabetes [51,52,53,54,55,56,57]. This evidence concerns the gene SLC5A2 and diabetes mellitus.